Just worthwhile remembering: in terms of TNFi anti-drug immunogenicity in autoimmune disease: RA is top of the pops (although dose spacing is worse) data from NOR-DRUM A, TDM in infliximab #ACR21 ABST1525 @RheumNow https://t.co/wfcA72wcLP https://t.co/mHppH6qYdY

ANA negative SLE! Lunch w/Dr. John P Atkinson. When I was in training @WUSTLrheum he bet that if you come across a case of ANA neg- SLE that is convincing, he will buy lunch. Great case of SLE following spont coronary artery dissection. #ThievesMarket #ACR21 Abst#TM18 @rheumnow https://t.co/TRyQaJ4kbR

Fun things at #ACR21. Abs1186 #Kardashian index: K-index = # of followers on Twitter/expected # of followers based on citations. ⭐️Only 1 program director (PD) had K-index>5, an "academic Kardashian" ⭐️Only 11 PDs on Twitter had >100 followers https://t.co/uH408ri5nY @Rheumnow https://t.co/d8VeyzAIcU

Impressive case of vasculitis – should be part of @ACRheum image bank #ThievesMarket #ACR21 Abst#TM20 @rheumnow https://t.co/YiBikROuzb

Pirfenidone in RA-ILD, TRAIL-1 study. Long-awaited. Early termination due to COVID led to under-powering. Slowed decline in FVC, especially in UIP pattern. Seemed to have less adverse events than we see with nintedanib. Abstr#L10 #ACR21 @RheumNow https://t.co/sYRDhG3u4y

Artificial neural network showed good generalizability and a high specificity with acceptable sensitivity in the detection of radiographic sacroiliitis. A tool for interpretation of sacroiliac radiographs as a part of the diagnostic approach @RheumNow #ACR21 Abst#1919 #ACRbest https://t.co/SdmomEWwya

New dimensions in cellular immunology. Great session, some which I understood. Kids with #JIA have more cytolytic pathway missense - some leads to macrophage activation syndrome #MAS Low NK cells in Juvenile Dermatomyositis. 9T112 #ACR21 @RheumNow https://t.co/5lUkqr65UM

Adipokines in RA ⚡️Highest Quartile Adiponectin associated w/ ⬆️ all-cause mortality HR 1.46 ⬆️ CV mortality HR 1.85 ⚡️Highest Quartile Leptine ⬆️ 25% all-cause mortality #ACR21 #Abst1645 @RheumNow https://t.co/O1NAbfMvif https://t.co/VVdgZHP1j5

b/tsDMARDs + tumor response in rheum irAEs Excellent point by @CCalabreseDO @LCalabreseDO: - despite progression in 5/10, DMARD contribution uncertain (bad cancer) - without DMARD, ICI would have had to stop crucial question, prospective study needed #ACR21 ABST1519 @RheumNow https://t.co/omJnTNVscH

The wave of the future? Study details immune profile which discriminates PsA from PsO using phenotyping of serum immune cell subsets & machine learning. Abs 1774 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/huNTY3IdRf https://t.co/3aW64pb9UW